Business Wire

Inversago Pharma receives IND clearance for Phase 2 trial of INV-202 in Diabetic Kidney Disease

Share

Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, has received FDA clearance of its Investigational New Drug (IND) application for a phase 2 study in Diabetic Kidney Disease (DKD) for INV-202, the Company’s lead program.

Inversago scientists identified Diabetic Kidney Disease as the most promising indication for a Phase 2 study, given its important unmet medical need. Such a study presents an opportunity to evaluate a comprehensive set of biomarker data in DKD that may also be relevant to a broad landscape of diabetic-related indications, including cardiometabolic and fibrotic complications.

INV-202, which is presently completing Phase 1b studies in patients with metabolic syndrome, showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversago’s lead program.

Dr. Glenn Crater, CMO at Inversago, stated: “This IND clearance is an important milestone for Inversago and marks the beginning of an important regulatory and clinical process in bringing a new therapeutic approach to patients suffering from Diabetic Kidney Disease.”

“We are excited to report this significant achievement for our first-in-class, peripherally-acting CB1 inverse agonist, which confirms our leadership in this field. We believe that CB1 blockers, such as INV-202, offer opportunities in multiple therapeutic areas,” added François Ravenelle, PhD, Chief Executive Officer of Inversago.

Inversago believes that peripheral CB1 blockade, either alone or in combination with other therapies, represents an opportunity to address the significant unmet medical need of DKD. As obesity, diabetes and their complications continue to affect more people around the world, the need for new therapies will only continue to grow.

About INV-202

INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including Diabetic Kidney Disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs.

About Diabetic Kidney Disease

Diabetic Kidney Disease (DKD) occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease. Like other chronic diseases, it is expected that multiple mechanisms are needed to achieve adequate control of this progressive disease. Inversago believes that peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.

About Inversago Pharma

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D), Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. For more information, visit inversago.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.
info@inversago.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

INNIO‘s next generation Jenbacher 3F engine offers significantly higher efficiency4.10.2022 15:07:00 EEST | Press release

INNIO announced today that it has launched its next generation Jenbacher Type 3F engine. This forms part of INNIO’s commitment to empower the transition to net zero with flexible, scalable, and resilient energy solutions and services. The new and improved Jenbacher Type 3F engine offers customers proven robustness and reliability while delivering up to two percentage points of efficiency boost, the engine line’s highest efficiency ever. In addition to delivering efficiency as high as 43.3% when operating on pipeline gas, the Type 3F engine is optimized for reduced total hydrocarbon (THC) emissions, future-proofed fuel flexibility, and enhanced serviceability. Moreover, the latest 3F technology is offered with a “Ready for H2” option and retrofittable for most of the installed Type 3 fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005681/en/ INNIO's next generation Jenbacher Type 3F engine has the line's highest e

Morrow Sodali Proud to Play a Key Role in Ukraine’s Successful Debt Deferral4.10.2022 15:00:00 EEST | Press release

Morrow Sodali, the global consulting firm to corporate and sovereign bond issuers, today published a report which provides a detailed account of their involvement in Ukraine’s recent transformational debt deferral. When the government of Ukraine needed to approach their foreign creditors for breathing space for repayments on billions of dollars in debt, they assembled a multinational team of leading financial and legal professionals to oversee the complex process and ensure all moving parts came together successfully and on time. With a team of dedicated experts in major financial centers around the world, Morrow Sodali took on the role of Information and Tabulation Agent for Ukraine’s consent solicitation. Using their proprietary real-time reporting system, BondWatch, which was developed by the Global Debt Services Team at Morrow Sodali, they were able to monitor in real-time the instructions they received from bondholders and identify when the requisite consents had been achieved on

Technology Company Enedym Inc. Announces New Collaboration with Toyota Tsusho Canada, Inc.4.10.2022 15:00:00 EEST | Press release

Enedym, Inc. (“Enedym”), the technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, today announced a strategic collaboration with Toyota Tsusho Canada, Inc. (“Toyota Tsusho”), a Toyota group company and general trading arm of Toyota Motor. Through the collaboration, Enedym will design and develop SRMs and inverters with rated nominal power of approximately 45kW for use in North America and Japan. The magnet-free electric motors will convert small commercial vehicles, or tuggers, commonly used at airports and manufacturing plants, from diesel fuel to battery or hydrogen power. Through Enedym’s advanced SRM motor technologies, the refitted tuggers will reduce carbon output and lower costs, while maintaining exceptional performance. The collaboration’s first output, an electric-powered commercial tugger, will be piloted at one of Toyota Tsusho’s affiliates located at one of Toyota Motor’s North American manufa

Velodyne Lidar Acquires AI Software Company Bluecity4.10.2022 13:48:00 EEST | Press release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced the company has acquired Bluecity, a Montreal-based artificial intelligence (AI) software company whose next-generation, lidar-based solutions solve safety, traffic and infrastructure issues. The all-stock acquisition reinforces Velodyne’s commitment to enabling customer success by delivering industry-leading, AI-powered autonomous vision solutions. The addition of Bluecity is expected to be immaterial to operating expenses and cash usage. Bluecity’s executive, software development and sales teams will join Velodyne. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005370/en/ Velodyne Lidar's Intelligent Infrastructure Solution, powered by Bluecity, installed at an intersection in San Jose, CA. Image credit: Velodyne Lidar Velodyne and Bluecity have been partnering for many years to deliver lidar-based solutions for smart city applications. Velodyne’s Intelligent

Eaton receives 2022 Automotive News PACEpilot recognition4.10.2022 13:30:00 EEST | Press release

Intelligent power management company Eaton today announced its Breaktor® circuit protection technology was named a 2022 Automotive News PACEpilot Innovation to Watch at the awards ceremony on Sept. 19. The recognition acknowledges post-pilot, pre-commercial innovations in the automotive and future mobility space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221004005233/en/ A product of Eaton’s eMobility business, the Breaktor technology is a new advanced circuit protection solution for battery electric vehicles (BEVs) that combines the function of fuses, pyro switches and contactors into a single coordinated device. As electric vehicle power levels increase, the Breaktor circuit protection solution solves the ever-increasing coordination challenge between fuses and contactors, while offering fast, safe and reliable protection for high-power battery and inverter systems. Eaton’s Breaktor technology has been selected by sev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom